Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Subscribe To Our Newsletter & Stay Updated